Proprietary Research

 
News Articles for Proprietary Research top ^
- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter CAMBRIDGE, Mass., Oct.
Sign-up for Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 investment picks
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT®) > FHACT® cervical cancer detection test has potential application for more than 2 million patients per year in the United States RUTHERFORD, N.J., Oct.
Sign-up for Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers investment picks
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK 1 ) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK 1 receptor antagonists are administered in combination with a 5-HT 3 receptor antagonist for the prevention of CINV.
Sign-up for Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV investment picks
http://media.marketwire.com/attachments/201411/291217_CellMedX_WhiteLogo_Small_FINAL.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161566&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Cell MedX Corp. (CMXC), Announces Acquisition of Proprietary Technology for Treatment of Diabetes and Related Ailments investment picks
RUTHERFORD, N.J., Sept.
Sign-up for Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE investment picks
~ Up to 10% Improvement in Power and Torque over Diesel; Targeted at Medium-Duty Truck Applications ~ VANCOUVER , Sept.
Sign-up for Westport Unveils Its Proprietary Enhanced Spark-Ignited Natural Gas System Targeting Medium-Duty Truck Applications investment picks
More than 150 Physicians in Attendance MOUNTAIN VIEW, Calif., Oct.
Sign-up for IRIDEX Reports Strong Attendance at European Workshop for its Proprietary MicroPulse® Laser Therapy for Retina and Glaucoma Applications investment picks
http://media.marketwire.com/attachments/201007/620832_QuickLogic-Logo-JPG.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1150441&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for QuickLogic Partners With Peel to Embed Its Proprietary SmartIR(TM) Technology Into Sensor Hub Solutions investment picks
Patent estate includes thirteen issued U.S. patents, thirty patents worldwide REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary Platform Technologies investment picks
2014/10/21
NEW YORK , Oct.
Sign-up for Credit Suisse launches proprietary company analyzer tool on the Bloomberg App Portal investment picks
Agreement represents the first distributor relationship outside the mainland United States for the company's ophthalmic formulations, which are now available by prescription in 36 states and US territories SAN DIEGO , Nov.
Sign-up for Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless™ Proprietary Formulations to Ophthalmologists in Puerto Rico investment picks
Dropless Cataract Therapy now available in California, Nevada, Oregon, and Hawaii SAN DIEGO , Dec.
Sign-up for Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Proprietary Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Proposed Sale  |  Next: Prospectus Supplement